Clinical Trials Logo

Polycystic Ovary Syndrome clinical trials

View clinical trials related to Polycystic Ovary Syndrome.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT06125587 Enrolling by invitation - Clinical trials for Polycystic Ovary Syndrome

Chiglitazar/Metformin in Non-obese Women With PCOS

Start date: November 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorders in women of reproductive age, and its prevalence rate is from 9% (NIH criteria) to 18% (Rotterdamcriteria). It is clinically characterized by hyperandrogenism, persistent anovulation, and polycystic ovarian changes. Moreover it is often accompanied by insulin resistance and obesity. Now, metformin is not only an antihyperglycemic drug, it also corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome. Chiglitazar is a novel peroxisome proliferation activated receptor (PPAR) agonist. Treatment of type 2 diabetes mellitus by moderate activation of PPARα, PPARγ and PPARδ, improving insulin sensitivity, regulating blood glucose, and promoting fatty acid oxidation and utilization. However, there is limited evidence for its treatment of insulin resistance in women with PCOS. Therefore, we applied chiglitazar and metformin to two groups of PCOS patients to understand their effects on insulin resistance.

NCT ID: NCT05830487 Enrolling by invitation - Clinical trials for Polycystic Ovary Syndrome

Advanced Glycation End Products and Dietary Intervention in Polycystic Ovary Patients

Start date: November 30, 2021
Phase: N/A
Study type: Interventional

Recently, the negative effects of advanced glycation end products on the pathophysiology of some diseases have attracted attention. This study was planned to evaluate the effect of dietary intervention and weight loss on serum advanced glycation and disease pathogenesis in patients with polycystic ovary syndrome.

NCT ID: NCT05760677 Enrolling by invitation - Clinical trials for PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM

Start date: October 1, 2022
Phase: Phase 1
Study type: Interventional

Purpose and significance: To explore the clinical efficacy and safety of Chiglitazar sodium in polycystic ovary syndrome with type 2 diabetes Methods: From October 2022 to September 2024, a total of 142 PCOS with T2DM patients admitted to Department of Endocrinology and Metabolism at the Affiliated Hospital of Nantong University were recruited. Participants are randomized in a ratio of 1:1 into two treatment groups of 71 participants: ① control group;②experimental group. After randomization, the control group was treated with lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone, and the patients in the experimental group were treated with lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (32mg QD) until the end of follow-up. The treatment and follow-up period totaled 3 months. Observe the body weight, menstrual cycle and blood glucose control and other related indicators. Type of study: randomized controlled, prospective, intervention study.

NCT ID: NCT05629858 Enrolling by invitation - Obesity Clinical Trials

Time Restricted Eating for the Treatment of PCOS

Start date: January 15, 2023
Phase: N/A
Study type: Interventional

Background: Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility among young women. This syndrome is a reproductive and endocrinological disorder that affects up to 18% of reproductive-aged women. To date, the only strategy shown to reverse PCOS is sustained weight loss of 5-10%. At present, daily calorie restriction (CR) is the main diet prescribed to patients with PCOS for weight loss. However, some women find it difficult to adhere to CR because calorie intake must be vigilantly monitored every day. Considering these problems with CR, another approach that limits timing of food intake, instead of number of calories consumed, has been developed. This diet is called "time restricted eating" (TRE) and involves confining the period of food intake to 6-8 h per day. TRE allows individuals to self-select foods and eat ad libitum during a large part of the day, which greatly increases compliance to these protocols. Recent findings show that TRE significantly reduces body weight, insulin resistance, and inflammation in adults with obesity. However, no randomized controlled trials have studied the role of TRE in treating PCOS. Accordingly, this study will compare the effects of TRE vs CR in females with PCOS over 6 months on body weight, androgen markers, inflammatory markers and insulin sensitivity. Methods: A 6-month randomized, controlled, parallel-arm trial will be implemented. Females with obesity and PCOS will be randomized to 1 of 3 groups: (1) 6-h TRE (ad libitum food intake from 1-7 pm, fasting from 7pm-1pm); (2) CR (25% energy restriction daily); or (3) control group (ad libitum intake with no meal timing restrictions).

NCT ID: NCT04508634 Enrolling by invitation - Clinical trials for Polycystic Ovary Syndrome

Treating Obese PCOS Patients With LSG vs. Met

Start date: November 1, 2020
Phase: Phase 4
Study type: Interventional

Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation disorders and/or hyperandrogenemia, and often accompanied by insulin resistance and other metabolic abnormalities. Sleeve gastrectomy was an effective threapy for severe obesity patients. This study will evaluate the clinical efficacy of sleeve gastrectomy for obese patients with PCOS. Mealwhile, the specific mechanism of sleeve gastrectomy for improving obese patients with PCOS will be explored through multi-group analysis.

NCT ID: NCT04215380 Enrolling by invitation - Clinical trials for Polycystic Ovary Syndrome

Effects of Gum Arabic Ingestion on Hormonal and Metabolic Changes in Patients With Polycystic Ovary Syndrome

GA&PCO
Start date: January 25, 2020
Phase: N/A
Study type: Interventional

To assess the effects on hormonal and metabolic changes in the PCOs patients after ingestion of Arabic gum

NCT ID: NCT02026323 Enrolling by invitation - Insulin Resistance Clinical Trials

The Effect of Acupuncture on Insulin Sensitivity Polycystic Ovary Syndrome

Start date: January 2014
Phase: N/A
Study type: Interventional

Hyperinsulinemia and insulin resistance play a key role in the pathogenesis of polycystic ovary syndrome (PCOS). Insulin resistance is significantly associated with the long-term risks of metabolic syndrome and cardiovascular disease. Acupuncture with electrical stimulation has in rats with dihydrotestosterone (DHT)-induced PCOS been shown to improve insulin sensitivity. Whether these findings can be translated into women with PCOS has not been investigated. Therefore, this study aims to evaluate whether acupuncture improves insulin sensitivity, ovulation rate and quality of life in women with PCOS. Our hypothesis is that acupuncture with combined manual and low-frequency electrical stimulation of the needles improves insulin resistance, induces ovulation and improves quality of life.

NCT ID: NCT01337531 Enrolling by invitation - Clinical trials for Polycystic Ovary Syndrome

Recombinant Versus Highly Purified FSH in Polycystic Ovary Syndrome (PCOS)

Start date: May 2011
Phase: Phase 2
Study type: Interventional

Control ovarian stimulation responses, pregnancy and miscarriage rates are indifferent when either recombinant or highly purified follicle stimulating hormone (FSH) is used.

NCT ID: NCT01162447 Enrolling by invitation - Clinical trials for Polycystic Ovarian Syndrome

Comparison of Bone Morphogenetic Protein-4 (BMP-4) and 7 Levels Between Control and Polycystic Ovarian Syndrome (PCOS) Patients.

Start date: February 2010
Phase: N/A
Study type: Observational

The investigators aim to compare the levels of bone morphogenetic protein-4 and -7 (BMP-4 and 7) in blood, follicular fluid and ovarian organ culture supernatant obtained from healthy subjects and polycystic ovarian syndrome (PCOS) patients.

NCT ID: NCT00955058 Enrolling by invitation - Clinical trials for Polycystic Ovary Syndrome

Evaluation of Serum Prostatic Specific Antigen (PSA) After Cyproterone Compound Treatment Compared With Oral Contraceptives Pill in Hirsute Polycystic Ovary Syndrome Patients

PSA
Start date: February 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of oral contraceptive on the serum free prostatic specific antigen (PSA)in women with polycystic ovary syndrome(PCOD)compared with cyproterone compound.